Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 225Ac-J591 + PNT2002 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
225Ac-J591 | Ac 225 MOAB J591|Ac-225 Anti-PSMA J591|Ac-225 rosopatamab tetraxetan | PSMA Antibody 20 | 225Ac-J591 is a radioconjugate comprising the alpha-radiation emitting radionuclide actinium-225 linked to a monoclonal antibody that targets PSMA (J591), which delivers radiation to PSMA-expressing tumor cells, potentially resulting in antitumor activity (PMID: 37922438). | |
PNT2002 | PNT-2002|PNT 2002|Lu-177-PNT2002|177Lu-PNT2002|[Lu-177]-PSMA-I and T | PNT2002 is a radioconjugate consisting of a PSMA-targeting ligand (PNT2002) attached to the radioisotope Lu 177, that binds to tumor cells expressing PSMA, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04886986 | Phase Ib/II | 225Ac-J591 + PNT2002 | 225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC | Suspended | USA | 0 |